Conatus Pharmaceuticals (CNAT) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CNAT Hot Sheet
Join SI Premium – FREE
Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q1 EPS of ($0.38), in-line with the analyst estimate of ($0.38).
For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Essential Utilities, Inc. (WTRG) Tops Q3 EPS by 4c
- Spyre Therapeutics, Inc. (SYRE) Misses Q3 EPS by 16c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
